AUTHORS
Lyra Morina, BS, Yeeun Paik2, Gavin Ghafoori3, Wilbur Song, MD, PhD4, Lynne Marsala5, Aleksandra Bourdine6, William Thomas7, Sadia Afrin, MS8, Emily K Phillips, MD9, Kelsey A Toth, PhD10, Kunal Shetty11, Michelle Becker-Hapak12, Sushanth Pureti13, Yoojin Ahn14, Elizabeth Juarez Diaz15, Hana Do16, Alice Yao Zhou, MD, PhD17, David Aaron Russler-Germain, MD, PhD18, Samuel Ameh, PhD19, Mark Foster20, Timothy Schappe21, Todd Fehniger, MD, PhD22
AFFILIATIONS
1 Washington University School of Medicine, St. Louis, Missouri, United States
2 Washington University School of Medicine, St. Louis, Missouri, United States
3 Washington University School of Medicine, St. Louis, Missouri, United States
4 Washington University School of Medicine, St. Louis, Missouri, United States
5 Washington University School of Medicine, St. Louis, Missouri, United States
6 Washington University School of Medicine, St. Louis, Missouri, United States
7 Washington University School of Medicine, St. Louis, Missouri, United States
8 Washington University School of Medicine, St. Louis, Missouri, United States
9 Washington University School of Medicine, St. Louis, Missouri, United States
10 Washington University School of Medicine, St. Louis, Missouri, United States
11 Washington University School of Medicine, St. Louis, Missouri, United States
12 Washington University School of Medicine, St. Louis, Missouri, United States
13 Washington University School of Medicine, St. Louis, Missouri, United States
14 Washington University School of Medicine, St. Louis, Missouri, United States
15 Washington University School of Medicine, St. Louis, Missouri, United States
16 Washington University School of Medicine, St. Louis, Missouri, United States
17 Washington University School of Medicine, St. Louis, Missouri, United States
18 Washington University School of Medicine, St. Louis, Missouri, United States
19 Washington University School of Medicine, St. Louis, Missouri, United States
20 Washington University School of Medicine, St. Louis, Missouri, United States
21 Washington University School of Medicine, St. Louis, Missouri, United States
22 Washington University School of Medicine, St. Louis, Missouri, United States
ABSTRACT
NK cells are activated in response to blood cancer targets by integrating signals from germline-DNA encoded activating and inhibitory receptors. However, malignant cell recognition via endogenous receptors is imperfect. Introducing a chimeric antigen receptor (CAR) facilitates NK responses to normally resistant cancer targets. Cytokine-induced memory-like (CIML or ML) NK cells are generated after brief stimulation of conventional (c)NK cells with IL-12, IL-15, and IL-18. ML NK cells have been translated to the clinic in multiple early phase clinical trials for hematologic and solid cancers. CD19-CAR expressing ML NK cells exhibit enhanced anti-tumor efficacy compared to CAR cNK cells. However, whether endogenous NK receptors can impact CAR signaling and activation remains unexplored. To address this knowledge gap, we investigated whether NK cell activating or inhibitory receptors can alter responses by CD19-CAR (41BB/ζ) ML NK cells.
We tested the role of the activating receptor CD16/FcγRIIIa on CAR-induced ML NK cell activation against CD19+CD20+ lymphoma Raji targets. Engaging CD16 via anti-CD20 mAb led to increased degranulation (sCD107a), IFN-γ production, and killing (p<0.01). Mechanistically, cross-linking of CAR and CD16 resulted in 2.1-2.5-fold increases in pZAP70, pAkt, and pS6 MFI over CAR alone (p<0.01). Furthermore, administering rituximab with CD19-CAR ML NK cells in NSG-IL15tg mice led to a significant decrease in Raji tumor burden compared to rituximab alone or CD19-CAR alone (p<0.01). The combination therapy also prolonged median survival from 23 to 41 days (p<0.0001). Thus, co-engagement of the activating receptor CD16 enhances CD19-CAR-directed ML NK cell responses. We next tested the role of activating receptors DNAM-1 (binds CD112, CD155) and NKG2D (binds MICA/B, ULBPs). CAR ML NK cells were co-cultured with Nalm6 targets that naturally express these ligands, with addition of receptor blocking mAbs. DNAM-1 blockade led to no change in CAR ML NK cell killing. In contrast, blocking NKG2D led to a significant decrease in NK cell degranulation, IFN-γ production, and 4 hour killing (p<0.01). Additionally, NKG2D blockade resulted in significant loss of Nalm6 tumor control during a 5-day Incucyte assay (p<0.001). Thus, endogenous NK cell activating receptors are required for the optimal CAR functional response by memory-like NK cells.
Alternatively, inhibitory receptors such as NKG2A (binds HLA-E) may diminish CAR ML NK cell activation. Indeed, blockade with anti-NKG2A mAb increased CD19-CAR ML NK cell degranulation and IFN-γ production against Nalm6, and increased short-term killing of Raji and Nalm6 (p<0.05). Furthermore, CAR ML NK cells with anti-NKG2A led to significantly improved control of Nalm6 tumor during a 5-day Incucyte assay (p<0.0001). Mechanistically, CAR and NKG2A cross-linking via its heterodimer CD94 demonstrated a 9.2-fold, 3.4-fold, 4.1-fold, and 2.1-fold decrease in pZAP70, pAkt, pS6, and p38 MFI, respectively, compared to CAR alone (p<0.05). In addition, NKG2A blockade in Nalm6-engrafted NSG-IL15tg mice treated with CD19 CAR ML NK cells improved tumor control relative to isotype control (p<0.01). Thus, NKG2A negatively regulates CD19-CAR signals within NK cells, thereby limiting their activity in vivo. Inhibitory killer cell immunoglobulin-like receptors (KIR) are a second type of NK cell checkpoint which bind HLA-class I molecules. Upon KIR3DL1 mAb blockade, CD19 CAR ML NK cells co-cultured with Ramos (HLA-Bw4+) demonstrated higher IFN-γ and TNF production, and degranulation (p<0.01). KIR3DL1- CAR NK cells also showed higher cytokine production and degranulation compared to their KIR3DL1+ counterparts (IFNγ, TNF, CD107a; p<0.05) indicating that KIR inhibitory receptors may hinder CAR ML NK cell activation.
Here, we discover that endogenous NK cell receptors significantly impact CAR-induced ML NK cell activation and killing in vitro and in vivo. Engaging CD16, blocking NKG2A, or blocking KIR3DL1 leads to enhanced cytotoxicity. Disrupting engagement of endogenous activating receptors such as NKG2D can reduce CAR NK cell responses, while others such as DNAM-1 appear irrelevant in a CAR context. Mechanistically, these functional modulations are reflected in alterations within signaling pathways linked to activation, proliferation, and survival. Our results inform CAR NK cell combination immunotherapies and strategies to engineer CARs that optimally integrate with endogenous NK cell biology.
DISCLOSURES
Lyra Morina, BS: Caralyst Health - Current equity holder in private company; Caralyst Health - Current Employment